A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

NCT01543698 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors Harboring a BRAF V600 Mutation

Interventions

DRUG: LGX818
DRUG: MEK162
DRUG: LEE011

Sponsor

Pfizer